Accepted Manuscript

Title: Uses of biologics in allergic diseases: what to choose and when

Author: Tara Vinyette Saco, Amber Pepper, Thomas B. Casale


PII: S1081-1206(18)30156-X

DOI: https://doi.org/10.1016/j.anai.2018.02.029

Reference: ANAI 2484

To appear in: Annals of Allergy, Asthma & Immunology

Received date: 8-1-2018 Revised date: 21-2-2018 Accepted date: 21-2-2018



Please cite this article as: Tara Vinyette Saco, Amber Pepper, Thomas B. Casale, Uses of biologics in allergic diseases: what to choose and when, *Annals of Allergy, Asthma & Immunology* (2018), https://doi.org/10.1016/j.anai.2018.02.029.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1

1	Uses of Biologics in Allergic Diseases: What to Choose and When
2	Tara Vinyette Saco M.D., Amber Pepper M.D., Thomas B. Casale M.D.
3	University of South Florida Morsani College of Medicine and James A. Haley Veterans Hospital
4	Tampa, FL.
5	
6	Corresponding author information:
7	Cover Letter
8	Corresponding Author:
9	Thomas B Casale, MD
10	University of South Florida Morsani College of Medicine Dept of Medicine
11	12901 Bruce B Downs Blvd, MDC 19
12	Tampa, FL 33612
13	813-974-8954
14	tbcasale@health.usf.edu
15	
16	Keywords: Asthma, urticaria, nasal polyps, atopic dermatitis, eosinophils, T2 high, T2 low,
17	interleukin 4, interleukin 5, interleukin 13, immunoglobulin E
18	meriesam i, meriesam e, meriesam is, manunogrocum z
19	Abbreviations:
20	1. Antigen binding fragment: Fab
21	2. Cryopyrin-associated periodic syndromes: CAPSs
22	3. Eczema area and severity index: EASI
23	4. Every # weeks: Q#W (e.g. Q2W, Q4W, Q8W)
24	5. Food and Drug Administration: FDA
25	6. Forced expiratory volume in one second: FEV ₁
26	7. Health-Related Quality of Life Score: HRQoL
27	8. High-affinity IgE receptor: FcεR1
28	9. High-affinity IgE receptor binding domain of IgE: Fcɛ3
29	10. Immunoglobulin E: IgE
30	11. Inhaled corticosteroids: ICS
31	12. Interleukin: IL
32	13. Investigator's global assessment: IGA
33	14. IL-5 Receptor: IL-5R
34	15. Least-squares: LS
35	16. Long-acting β agonists: LABAs
36	17. Nucleotide-binding domain, leucine-rich family, pyrin domain containing 3 gene: <i>NLRP3</i>
37	18. Prostaglandin D2: PD2
38	19. Relative risk: RR
39	20. Standardized mean difference: SMD
40	21. Subcutaneous: SC
41	22. Tumor necrosis factor: TNF
42	23. Urticaria Activity Score: UAS7
43	24. Visual analog scale: VAS
44	
45	Author Note:
46	Funding source: None

Download English Version:

https://daneshyari.com/en/article/8711759

Download Persian Version:

https://daneshyari.com/article/8711759

<u>Daneshyari.com</u>